Media Healthcare Providers, https://www.businesswire.com/news/home/20220401005459/en/. With the new sites talent, strategic location on the West Coast, and potential for future capacity growth, we are confident that we will help our partners deliver T cell and CAR-T therapies to offer patients hope.. As part of a long-term manufacturing and services agreement, FUJIFILM Diosynth Biotechnologies will support the production of Ataras promising clinical and commercial-stage allogeneic cell therapies at the site, including tabelecleucel (tab-cel), currently in phase 3 clinical development and under review to support registration in Europe, for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+PTLD). Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB). Atara retains the recently established Thousand Oaks-based Atara Research Center (ARC), which is fully operational and will house Ataras Pre-Clinical, Translational Sciences, Manufacturing Process Sciences, and Analytical Development teams to further drive innovation by leveraging the Companys unique and differentiated allogeneic cell therapy platform. Strength, Multiple These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Ataras cash resources and need for additional capital; and other risks and uncertainties affecting Ataras and its development programs, including those discussed in Ataras filings with the Securities and Exchange Commission (SEC), including in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of the Companys most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. United States of America "Global Multicancer Screening Market to Reach $7.78 Billion by 2032." Industry Overview. The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies global network, which is a subsidiary of FUJIFILM Corporation, and a world-leading contract development and manufacturing organization (CDMO). Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies existing global footprint and to bolster the expansion of our advanced therapies CDMO business., FUJIFILM Diosynth Biotechnologies is a highly respected industry-leading manufacturing and development organization that shares our pioneering culture and belief that allogeneic cell therapies will transform the future of medicine, said Pascal Touchon, president and chief executive officer, Atara. The facility is the newest addition to FUJIFILM Diosynth Biotechnologies global portfolio of manufacturing sites which include facilities in College Station, Texas, USA, Research Triangle Park, North Carolina, USA, Teesside, UK, and Hillerd, Denmark. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. Access. Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Upon closing, the upfront consideration, along with the reduction in operating expenses, in addition to Ataras existing cash, cash equivalents and short-term investments is expected to fund Ataras planned operations into Q4 2023, beyond the anticipated completion of the randomized, placebo-controlled Phase 2 study of ATA188, the Companys investigational off-the-shelf T-cell candidate that has the potential to reverse disability in progressive multiple sclerosis. United States of America +45 7741 6000, 101 J Morris Commons Lane Atara Biotherapeutics Enters Strategic Manufacturing Partnership with FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. Billingham, TS23 1LH +44 1642 363511, 2430 Conejo Spectrum Street Investors FUJIFILM Diosynth Biotechnologies will also expand use of the Thousand Oaks site to manufacture a broader portfolio of cell therapies by leveraging the experience and expertise of the manufacturing and quality staff who transitioned to FUJIFILM Diosynth Biotechnologies. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire Ataras T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California for USD 100 million upfront, retaining current manufacturing and quality staff at the site. "We are thrilled that through this acquisition we will add approximately 140 talented staff from Atara's cell therapy manufacturing facility to the FUJIFILM Diosynth . Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Through this acquisition Fujifilm can extend its CDMO offering to advanced cell therapies. As part of the agreement, FUJIFILM Diosynth Biotechnologies and Atara will enter into a long-term manufacturing and services agreement, which could extend to ten years to support the production of Ataras clinical pipeline, which includes tabelecleucel (tab-cel) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+PTLD). With the new sites talent, strategic location on the West Coast, and potential for future capacity growth, we are confident that we will help our partners deliver T cell and CAR-T therapies to offer patients hope.. In connection with this announcement, Atara will host a webcast and conference call today at 4pm PST / 7pm EST. Atara Biotherapeutics, Inc. . This partnership and acquisition was first announced in January 2022. The agreement is expected to reduce Ataras planned operating expenses over the multiyear period. The agreement is expected to reduce Ataras planned operating expenses over the multiyear partnership period. Cookies are important to the proper functioning of a site. The 90,000 sq. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of . At closing, Fujifilm plans to offer positions to approximately 140 current highly-skilled manufacturing and quality staff at the site. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. HCRx has $6.3 billion in cumulative capital commitments with offices in Stamford (CT . Following completion of the transaction, FDB, a leading contract development and manufacturing organization (CDMO) in advanced therapies, will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel), under regulatory review in Europe for EBV+ PTLD, ATA188 for multiple sclerosis, and allogeneic CAR T therapies, ATA3271 and ATA3219. Fujifilm Completes Acquisition of a Dedicated Cell Therapy - IMAPAC FUJIFILM Diosynth Biotechnologies California, Inc. entered into an asset purchase agreement to acquire T-Cell Operations and Manufacturing Facility in Thousand Oaks, California from Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) for $100 million on January 26, 2022. FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. An archived replay will be available on the Company's website for 30 days. April 28, 2023. Thousand Oaks, CA 91320 For more information, please visit: https://www.fujifilmholdings.com. Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need. ATOM is a 90,000 ft cutting edge T-cell therapy manufacturing facility fully qualified to support clinical and commercial production and designed with the flexibility to expand to support various production requirements and capacities. ATRA - Atara Biotherapeutics, Inc. Stock Price and Quote - FINVIZ.com Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. 805-456-4772 Because such statements deal with future events and are based on Ataras current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. TOKYO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. SOUTH SAN FRANCISCO, Calif., April 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop .
Fossil Formation Simulation,
Dr Tam Credentials,
Ascension Symptoms March 2021,
Aac 9 Inch 300 Blackout Upper,
Barrel Shroud 9mm,
Articles A
